AAAAAA
Results: 1-25/29
Authors:
SHARPLES K
FLEMING TR
MACMAHON S
MOORE A
REID I
SCOGGINS B
Citation: K. Sharples et al., MONITORING CLINICAL-TRIALS, New Zealand medical journal, 111(1072), 1998, pp. 322-325
Authors:
GOLDBERG RM
FLEMING TR
TANGEN CM
MOERTEL CG
MACDONALD JS
HALLER DG
LAURIE JA
Citation: Rm. Goldberg et al., SURGERY FOR RECURRENT COLON-CANCER - STRATEGIES FOR IDENTIFYING RESECTABLE RECURRENCE AND SUCCESS RATES AFTER RESECTION, Annals of internal medicine, 129(1), 1998, pp. 27
Authors:
LIN DY
FLEMING TR
DEGRUTTOLA V
Citation: Dy. Lin et al., ESTIMATING THE PROPORTION OF TREATMENT EFFECT EXPLAINED BY A SURROGATE MARKER, Statistics in medicine, 16(13), 1997, pp. 1515-1527
Authors:
SHEN Y
FLEMING TR
Citation: Y. Shen et Tr. Fleming, WEIGHTED MEAN SURVIVAL TEST STATISTICS - A CLASS OF DISTANCE TESTS FOR CENSORED SURVIVAL-DATA, Journal of the Royal Statistical Society. Series B: Methodological, 59(1), 1997, pp. 269-280
Authors:
MARTINO RL
FLEMING TR
MORRELL LM
ARDALAN B
RICHMAN SP
MACDONALD JS
Citation: Rl. Martino et al., PHASE-II TRIAL OF LOW-DOSE N-(PHOSPHONACETYL)-DISODIUM L-ASPARTIC ACID AND HIGH-DOSE 24-HOUR INFUSIONAL 5-FLUOROURACIL IN ADVANCED GASTRIC ADENOCARCINOMA - A SOUTHWEST-ONCOLOGY-GROUP STUDY, Investigational new drugs, 14(4), 1996, pp. 419-421
Authors:
FLEMING TR
DEMETS DL
Citation: Tr. Fleming et Dl. Demets, SURROGATE END-POINTS IN CLINICAL-TRIALS - ARE WE BEING MISLED, Annals of internal medicine, 125(7), 1996, pp. 605-613
Authors:
FLEMING TR
NEATON JD
GOLDMAN A
DEMETS DL
LAUNER C
KORVICK J
ABRAMS D
BEERS D
LOVELESS K
MARTINEZ N
MESARD CA
REVES RR
ROUFF JA
KLEIN T
MCDONALD R
SLOTTEN R
BROSGART C
DREW L
FESSEL J
HUDSON R
LOPEZ C
THOMPSON S
KUMI JO
MASTROPOLAK D
SARAVOLATZ LD
KERKERING TM
HIGGINSON RA
GERNON L
BAR M
MENDEZ D
ERNST J
SCOTT J
FINLEY B
WARD D
WISNIEWSKI T
BRANDON W
WALTER J
CALHOUN C
EBRIGHT JR
SCHUMAN P
BINCSIK A
SWANSON K
WINSLOW D
SHERIDAN A
TAYLOR V
PEREZ G
ELSADR W
GUITY C
JULEAU J
SALVATI S
DOWLING C
SALVADOR GI
BURNS AJ
LAM SH
CHILDRESS JF
DEETS DL
FLEMING TR
MEYER KH
POLLARD RB
OFALLON JR
RAHAL JJ
WALTERS L
WHITNEYWILLIAMS P
WHITLEY RJ
Citation: Tr. Fleming et al., INSIGHTS FROM MONITORING THE CPCRA DIDANOSINE ZALCITABINE TRIAL, Journal of acquired immune deficiency syndromes and human retrovirology, 10, 1995, pp. 9-18
Authors:
MACDONALD JS
FLEMING TR
PETERSON RF
BERENBERG JL
MCCLURE S
CHAPMAN RA
EYRE HJ
SOLANKI D
CRUZ AB
GAGLIANO R
ESTES NC
TANGEN CM
RIVKIN S
Citation: Js. Macdonald et al., ADJUVANT CHEMOTHERAPY WITH 5-FU, ADRIAMYCIN, AND MITOMYCIN-C (FAM) VERSUS SURGERY ALONE FOR PATIENTS WITH LOCALLY ADVANCED GASTRIC ADENOCARCINOMA - A SOUTHWEST-ONCOLOGY-GROUP STUDY, Annals of surgical oncology, 2(6), 1995, pp. 488-494
Authors:
BROWN TD
FLEMING TR
GOODMAN PJ
MACDONALD JS
PUGH RP
OROURKE T
Citation: Td. Brown et al., A RANDOMIZED TRIAL OF 2 SCHEDULES OF TRIMETREXATE VERSUS 5-FLUOROURACIL IN ADVANCED COLORECTAL-CANCER - A SOUTHWEST-ONCOLOGY-GROUP STUDY, Anti-cancer drugs, 6(2), 1995, pp. 219-223
Authors:
LEICHMAN CG
FLEMING TR
MUGGIA FM
TANGEN CM
ARDALAN B
DOROSHOW JH
MEYERS FJ
HOLCOMBE RF
WEISS GR
MANGALIK A
MACDONALD JS
Citation: Cg. Leichman et al., PHASE-II STUDY OF FLUOROURACIL AND ITS MODULATION IN ADVANCED COLORECTAL-CANCER - A SOUTHWEST-ONCOLOGY-GROUP STUDY, Journal of clinical oncology, 13(6), 1995, pp. 1303-1311
Authors:
MOERTEL CG
FLEMING TR
MACDONALD JS
HALLER DG
LAURIE JA
TANGEN CM
UNGERLEIDER JS
EMERSON WA
TORMEY DC
GLICK JH
VEEDER MH
MAILLIARD JA
Citation: Cg. Moertel et al., INTERGROUP STUDY OF FLUOROURACIL PLUS LEVAMISOLE AS ADJUVANT THERAPY FOR STAGE-II DUKES B2 COLON-CANCER, Journal of clinical oncology, 13(12), 1995, pp. 2936-2943
Authors:
FABIAN C
GIRI S
ESTES N
TANGEN CM
POPLIN E
VOGEL S
GOODWIN W
RIVKIN S
FLEMING TR
MACDONALD JS
Citation: C. Fabian et al., ADJUVANT CONTINUOUS-INFUSION 5-FU, WHOLE-ABDOMINAL RADIATION, AND TUMOR BED BOOST IN HIGH-RISK STAGE-III COLON-CARCINOMA - A SOUTHWEST-ONCOLOGY-GROUP PILOT-STUDY, International journal of radiation oncology, biology, physics, 32(2), 1995, pp. 457-464
Authors:
DEMETS DL
FLEMING TR
WHITLEY RJ
CHILDRESS JF
ELLENBERG SS
FOULKES M
MAYER KH
OFALLON J
POLLARD RB
RAHAL JJ
SANDE M
STRAUS S
WALTERS L
WHITLEYWILLIAMS P
Citation: Dl. Demets et al., THE DATA AND SAFETY MONITORING BOARD AND ACQUIRED-IMMUNE-DEFICIENCY-SYNDROME (AIDS) CLINICAL-TRIALS, Controlled clinical trials, 16(6), 1995, pp. 408-421
Authors:
FLEMING TR
BROWN TD
ROSS SW
MACDONALD JS
Citation: Tr. Fleming et al., PHASE-II TRIAL OF TRIMETREXATE IN ADVANCED ESOPHAGEAL CANCER - A SOUTHWEST-ONCOLOGY-GROUP STUDY, Investigational new drugs, 13(4), 1995, pp. 363-365
Authors:
SCHAPER C
FLEMING TR
SELF SG
RIDA WN
Citation: C. Schaper et al., STATISTICAL ISSUES IN THE DESIGN OF HIV VACCINE TRIALS, Annual review of public health, 16, 1995, pp. 1-22
Authors:
BERENBERG JL
TANGEN C
MACDONALD JS
HUTCHINS LF
NATALE RB
OISHI N
GUY JT
FLEMING TR
Citation: Jl. Berenberg et al., PHASE-II STUDY OF 5-FLUOROURACIL AND FOLINIC ACID IN THE TREATMENT OFPATIENTS WITH ADVANCED GASTRIC-CANCER - A SOUTHWEST-ONCOLOGY-GROUP STUDY, Cancer, 76(5), 1995, pp. 715-719
Authors:
ANDERSON GL
FLEMING TR
Citation: Gl. Anderson et Tr. Fleming, MODEL MISSPECIFICATION IN PROPORTIONAL HAZARDS REGRESSION, Biometrika, 82(3), 1995, pp. 527-541
Authors:
GRAMBSCH PM
THERNEAU TM
FLEMING TR
Citation: Pm. Grambsch et al., DIAGNOSTIC PLOTS TO REVEAL FUNCTIONAL FORM FOR COVARIATES IN MULTIPLICATIVE INTENSITY MODELS, Biometrics, 51(4), 1995, pp. 1469-1482
Authors:
MOERTEL CG
FLEMING TR
MACDONALD JS
HALLER DG
LAURIE JA
TANGEN CM
UNGERLEIDER JS
EMERSON WA
TORMEY DC
GLICK JH
VEEDER MH
MAILLIARD JA
GRAFF J
Citation: Cg. Moertel et al., FLUOROURACIL PLUS LEVAMISOLE AS EFFECTIVE ADJUVANT THERAPY AFTER RESECTION OF STAGE-III COLON-CARCINOMA - A FINAL REPORT, Annals of internal medicine, 122(5), 1995, pp. 321-326
Authors:
FLEMING TR
PRENTICE RL
PEPE MS
GLIDDEN D
Citation: Tr. Fleming et al., SURROGATE AND AUXILIARY END-POINTS IN CLINICAL-TRIALS, WITH POTENTIALAPPLICATIONS IN CANCER AND AIDS RESEARCH, Statistics in medicine, 13(9), 1994, pp. 955-968
Authors:
FLEMING TR
Citation: Tr. Fleming, SURROGATE MARKERS IN AIDS AND CANCER TRIALS, Statistics in medicine, 13(13-14), 1994, pp. 1423-1435
Authors:
BUKOWSKI RM
TANGEN CM
PETERSON RF
TAYLOR SA
RINEHART JJ
EYRE HJ
RIVKIN SE
FLEMING TR
MACDONALD JS
Citation: Rm. Bukowski et al., PHASE-II TRIAL OF DIMETHYLTRIAZENOIMIDAZOLE CARBOXAMIDE IN PATIENTS WITH METASTATIC CARCINOID - A SOUTHWEST-ONCOLOGY-GROUP STUDY, Cancer, 73(5), 1994, pp. 1505-1508
Authors:
LIN DY
FLEMING TR
WEI JL
Citation: Dy. Lin et al., CONFIDENCE BANDS FOR SURVIVAL CURVES UNDER THE PROPORTIONAL HAZARDS MODEL, Biometrika, 81(1), 1994, pp. 73-81
Authors:
MOERTEL CG
FLEMING TR
MACDONALD JS
HALLER DG
LAURIE JA
Citation: Cg. Moertel et al., HEPATIC TOXICITY ASSOCIATED WITH FLUOROURACIL PLUS LEVAMISOLE ADJUVANT THERAPY, Journal of clinical oncology, 11(12), 1993, pp. 2386-2390
Authors:
FLEMING TR
DEMETS DL
Citation: Tr. Fleming et Dl. Demets, MONITORING OF CLINICAL-TRIALS - ISSUES AND RECOMMENDATIONS, Controlled clinical trials, 14(3), 1993, pp. 183-197